

New vaccines and old can curb drug resistance

July 20 2022, by Sanjeet Bagcchi



Biochemists examine bacteria samples from Argentina's hospitals at Malbrán Institute in Buenos Aires to test for antimicrobial resistance (AMR). A WHO report says almost 5 million deaths worldwide, were linked to AMR in 2019. Credit: [Sarah Pabst/WHO](#)

Trials of new vaccine candidates must be accelerated and existing vaccine use stepped up to prevent life-threatening infections that can no longer be beaten by antimicrobial medicines, the World Health

Organization (WHO) has urged.

Antimicrobial resistance (AMR)—when bacteria, viruses, fungi or parasites become unresponsive to medicines such as [antibiotics](#) or antivirals—has been identified by the WHO as one of the biggest global threats to [public health](#) and is growing worldwide.

In 2019, an estimated 4.95 million deaths were associated with AMR, says a new WHO [report](#) which is the first ever on the pipeline of bacterial vaccines under development.

An estimated 5.7 million deaths occur each year in low- and [middle-income countries](#) which could have been prevented if the right antibiotics were used, according to the UN agency.

Infections linked with ventilators and catheters are up to 13 times higher in [low-resource countries](#) than in the United States, while [hospital infections](#) among newborns in low-income countries are up to 20 times higher than in [high-income countries](#), WHO figures show.

But the WHO report says that vaccines can be powerful tools to ward off such infections, potentially helping to minimize the use of antimicrobial medicines.

"Preventing infections using vaccination reduces the use of antibiotics, which is one of the main drivers of AMR," said WHO assistant director-general for antimicrobial resistance Hanan Balkhy. "Yet, of the top six bacterial pathogens responsible for deaths due to AMR, only one, Pneumococcal disease [*Streptococcus pneumoniae*] has a vaccine."

Balkhy says affordable and equitable access to vaccines against such infections is urgently needed.

[A study](#) published earlier this year in *The Lancet*, found that AMR death rates were highest in a number of poorer countries, while also identifying a lack of data from many lower-income countries.

David Sack, professor of international health at Johns Hopkins Bloomberg School of Public Health, in Baltimore, U.S., says effective vaccines offer "a partial solution."

"When an effective vaccine prevents an infection, it does not care if the infection was sensitive or resistant to antibiotics, it reduces the total incidence of the infection and thereby reduces the number of infections caused by resistant strains as well as sensitive ones," he told SciDev.Net.

The WHO commissioned the report to improve awareness of the vaccines currently in development to fight bacteria that are commonly found to be resistant, and provide guidance on necessary action and investment.

It identifies 61 vaccine candidates that were in different stages of human testing last year and 94 [vaccine](#) candidates in development, but not yet being tested on humans, and says trials for these must be accelerated.

Equitable access

The report also calls for fair, impartial and international access to the vaccines that already exist, particularly for people who need them most in resource-poor settings.

Vaccines are currently available against what the WHO describes as diseases caused by four priority pathogens: [pneumococcal disease](#), haemophilus influenzae type b (Hib), tuberculosis (TB), and typhoid. However, the BCG jab used against TB does not offer adequate protection against the disease and more effective vaccines need to be

found urgently, the report recommends.

Vaccines against the other three infections are effective and should be deployed more widely to help reduce the use of antibiotics and prevent further deaths, the WHO urged.

However, global health experts stress the need for broader strategies to combat drug resistance. George M. Varghese, professor of infectious diseases at the Christian Medical College in Vellore, India, said: "Although vaccines are one of the greatest discoveries in human history saving millions of lives, it is unlikely to be a key solution for the silent pandemic of AMR.

"Making the effective vaccines against influenza, COVID-19 and pneumococcal pneumonia available in an equitable and accessible manner will reduce unnecessary antibiotic usage to some extent and thereby reduce the problem of AMR to some degree," Varghese told SciDev.Net. In some cases antibiotics are wrongly prescribed for such viruses due to lack of diagnostics.

But he also pointed to the need for multiple other measures including ensuring appropriate antimicrobial use, better [infection](#) control measures, controlling the use of antibiotics in animal rearing, developing new antimicrobials and diagnostics, and improved surveillance of AMR and antimicrobials.

Agnimita Giri Sarkar, consultant pediatrician at the Institute of Child Health in Kolkata, India, says overuse and inappropriate use of antimicrobials must be stopped urgently and public awareness improved along with hygiene and sanitation.

"In developing countries, supply of over-the-counter antibiotics without prescription or with old prescription, and self-medication with incorrect

knowledge about antibiotics, are posing a great threat contributing to antimicrobial resistance," she told SciDev.Net.

The WHO is working on an initiative called SECURE which seeks to expand access to essential antibiotics where they are needed, while ensuring their appropriate use.

Participating countries will gain access to new antibiotics developed to treat drug-resistant infections, as well as older ones that are not widely available or are subject to supply chain disruptions, the health body says.

Provided by SciDev.Net

Citation: New vaccines and old can curb drug resistance (2022, July 20) retrieved 17 December 2022 from <https://medicalxpress.com/news/2022-07-vaccines-curb-drug-resistance.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.